MPP+‐induced COX‐2 activation and subsequent dopaminergic neurodegeneration
- 21 April 2005
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 19 (9) , 1134-1136
- https://doi.org/10.1096/fj.04-2457fje
Abstract
The importance of cyclooxygenase-2 (COX-2) in mediating Parkinson's disease (PD) was suggested in reports, indicating that COX-2 selective inhibitors or genetic knockout reduce 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic (DA) neurotoxicity in a mouse model of PD. However, cell types and mechanisms underlying the activation of COX-2 have not been clearly elucidated in these animal studies. Using primary neuron-glia cultures, we aimed to determine 1) whether microglia participate in 1-methyl-4-phenylpryridinium (MPP)-induced COX-2 activation and 2) whether the activation of COX-2 contributes to subsequent neurotoxicity. MPP, in a concentration-dependent manner, increased prostaglandin E2 (PGE2) production in mixed neuron-microglia cultures but not in enriched neuron, microglia, or astroglia cultures nor in mixed neuron-astroglia cultures. MPP-induced PGE2 increase was completely abolished by treatment with DuP697, a COX-2 selective inhibitor. DuP697 also significantly reduced MPP-induced DA neurotoxicity as determined by DA uptake assay. Immunocytochemistry and confocal microscopy studies showed enhanced COX-2 expression in both microglia and neurons after MPP treatment. However, neuronal increase in COX-2 expression was not totally dependent on the production of PGE2 from microglia, since microglia deficient in COX-2 only attenuated, but did not completely block, MPP-increased PGE2 production in mixed neuron-microglia cultures, suggesting that part of PGE2 production was originated from neurons. Together, these results indicate that MPP-induced COX-2 expression and subsequent PGE2 production depend on interactions between neurons and microglia. Microgliosis may also be responsible for the COX-2 activation in neurons, leading to the enhanced DA neurotoxicity, which, in turn, reinforces microgliosis. Thus inhibition of microgliosis and COX-2 activity may stop this vicious circle and be valuable strategies in PD therapy.Keywords
This publication has 32 references indexed in Scilit:
- Andrographolide Reduces Inflammation-Mediated Dopaminergic Neurodegeneration in Mesencephalic Neuron-Glia Cultures by Inhibiting Microglial ActivationThe Journal of Pharmacology and Experimental Therapeutics, 2004
- The Scientific Basis for the Current Treatment of Parkinson's DiseaseAnnual Review of Medicine, 2004
- NADPH Oxidase Mediates Lipopolysaccharide-induced Neurotoxicity and Proinflammatory Gene Expression in Activated MicrogliaJournal of Biological Chemistry, 2004
- Critical role of microglial NADPH oxidase‐derived free radicals in the in vitro MPTP model of Parkinson's diseaseThe FASEB Journal, 2003
- MICROGLIA AS MEDIATORS OF INFLAMMATORY AND DEGENERATIVE DISEASESAnnual Review of Neuroscience, 1999
- Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions?report of a workshopMovement Disorders, 1998
- Glial pathology but absence of apoptotic nigral neurons in long‐standing Parkinson's diseaseMovement Disorders, 1998
- Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouseCell, 1995
- NORMAL MPTP BINDING IN PARKINSONIAN SUBSTANTIA NIGRA: EVIDENCE FOR EXTRANEURONAL TOXIN CONVERSION IN HUMAN BRAINThe Lancet, 1985
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983